Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Ifeanyichukwu Ifechidere: The Laboratory Challenges of Measuring Direct Factor Xa Inhibitors
Ifeanyichukwu Ifechidere/LinkedIn
Oct 27, 2026, 11:41

Ifeanyichukwu Ifechidere: The Laboratory Challenges of Measuring Direct Factor Xa Inhibitors

Ifeanyichukwu Ifechidere, Specialist Biomedical Scientist at Sheffield Teaching Hospitals, shared a post on LinkedIn:

“Two patients. Same diagnosis. Same Anti-Xa result. Does it mean the same thing?

Imagine two patients, both diagnosed with a pulmonary embolism and both receiving a direct oral anticoagulant (DOAC).

Their laboratory results come back with the same anti-Xa assay result.

Can we conclude that they have the same anticoagulant activity, the same bleeding risk, or the same level of protection against thrombosis?

Not so fast!

This is where understanding anti-Xa testing becomes particularly important in coagulation.

First, what are we actually measuring?

Apixaban and rivaroxaban are direct factor Xa inhibitors.

Anti-Xa assays can be used to estimate their concentrations in plasma, but the interpretation depends on the assay method.

Here are five things we need to consider:

1. Which DOAC is the patient taking?

Apixaban and rivaroxaban are both factor Xa inhibitors, but they have different pharmacokinetic profiles and dosing regimens.

A result obtained using an apixaban-calibrated assay should not automatically be interpreted using rivaroxaban-specific expectations, or vice versa.

2. Was the assay calibrated for the correct drug?

Drug-calibrated anti-Xa assays are designed to estimate the concentration of a specific DOAC, commonly reported in ng/mL.

Heparin-calibrated anti-Xa assays produce results in different units and cannot be interpreted as though they were drug-specific concentrations.

The same number does not necessarily mean the same thing across different assays.

3. When was the last dose taken?

A result collected near peak concentration may look very different from one collected immediately before the next dose.

Without knowing the time of the last dose, interpreting the result can be misleading.

4. What is happening clinically?

Renal function, liver function, drug interactions, adherence, bleeding, suspected thrombosis and the reason for testing all influence how the result should be interpreted.

Two patients with the same diagnosis may have very different clinical circumstances.

5. Is the result within an expected on-treatment range?

Expected DOAC concentrations vary with the drug, dose, indication and time since administration.

These ranges are descriptive, not validated therapeutic targets for routine dose adjustment.

A result within an expected range does not guarantee efficacy or safety, and a result outside it does not independently establish treatment failure.

The take-home message

An anti-Xa result is not a clinical diagnosis.

Before interpreting it, ask:

  • Which anticoagulant is involved?
  • Which assay and calibration were used?
  • When was the last dose taken?
  • What is the clinical question?
  • Are the units and reference information appropriate?

The coagulation laboratory’s job isn’t just to report a number.

It’s to help ensure that the number is understood in the right context.

Save this post for your next DOAC-related laboratory discussion.”

Ifeanyichukwu Ifechidere: The Laboratory Challenges of Measuring Direct Factor Xa Inhibitors

Other posts featuring Ifeanyichukwu Ifechidere on Hemostasis Today.

anti-Xa Apixaban Direct Factor Xa Inhibitors DOACs Health Hematology Hemostasis Hemostasis News Hemostasis Today Ifeanyichukwu Ifechidere Medicine Rivaroxaban
NewsFeed